Wissenschaft & Forschung / CCC Platforms / Drug & Target Screening (CCC-DTS)

Drug & Target Screening Unit (CCC-DTSU)

DTSU

Mission

With an ever growing field of knowledge, target identification and drug development in oncology it is necessary to build strategic alliances between academic institutions and other important players including scientific organisations, international health agencies and pharmaceutical industry. Such alliances merge clinical experience, basic research expertise and modern biotechnology to guarantee successful drug development programs resulting in an improvement of cancer treatment options.

Function

DTSU is a translational research unit which speeds up the process of drug development and the design of effective cancer therapy in cooperation with important institutions engaging in the identification of treatment targets and the applicability of their function modulation in the clinic. The unit provides a drug testing platform, merges clinical data, genomics, proteomics and biomarkers to generate evidence-based surrogate endpoints which predict drug efficacy in oncology and hematology.

Facility

The unit is part of the Comprehensive Cancer Center (CCC) of the Medical University Vienna and the General Hospital and is located within the Department of Medicine I. Its core facility operates in the tumor microenvironment laboratory within the Clinical Division of Hematology and Hemostaseology.

DTSU possesses modern research infrastructure, a well trained research team, ex vivo models for drug testing and target validation and is connected to the microarray and proteomic units.

DTSU has access to primary materials and tissue banks from patients with hematological malignancies and solid tumors, their clinical characteristics, genomics and proteomics and biomarkers to generate evidence-based surrogate endpoints which predict drug efficacy and accelerate drug development in oncology and hematology.

For further information:

» DTSU brochure
» DTSU folder

Verantwortlich:

Assoc.-Prof. Dr. Medhat Shehata
Universitätsklinik für Innere Medizin I
Medizinische Universität Wien
Währinger Gürtel 18-20
A-1090 Wien

Tel.: +43 (0)1 40400 62170
eMail: medhat.shehata[at]meduniwien.ac.at

Univ.-Prof. Dr. Ulrich Jäger
Universitätsklinik für Innere Medizin I
Medizinische Universität Wien
Währinger Gürtel 18-20
A-1090 Wien

Tel: +43 (0)1 40400 44090; 44100
eMail: ulrich.jaeger[at]meduniwien.ac.at

» www.ccc.ac.at/dtsu

2nd Symposium of CCC-Drug & Target Screening Unit (DTSU)

Tumor Microenvironment: Innovation in Cancer Therapy

29th of October 2012, Vienna

Dear Colleagues,

On behalf of the organizing Committee: Prof. C. Zielinski, Prof. U. Jäger and Ass. Prof. M. Shehata, I would like to invite you to attend the 2nd Drug & Target Screening Unit DTSU/CCC symposium “Tumor Microenvironment: Innovation in Cancer Therapy”, which takes place at the Medical University of Vienna (AKH) on the 29th of October 2012 (9:00-18:00) (HS4).

Scope: Excellent national and international experts from academic institutes, pharmaceutical industries, basic researchers, clinicians, young scientists and students are gathering during the symposium to exchange thoughts and novel concepts for improving cancer treatment. The symposium addresses the biology of tumor microenvironment and focuses on the exploration of innovative approaches which target the microenvironment to achieve a better therapy outcome.

Topics: The major topics are: 1) Microenvironment in solid tumors and hematological malignancies, 2) Immunological aspects of tumor microenvironment, 3) stromal compartment of microenvironment and 4) Signaling through microenvironment and stem cell niches.

Admission: Free

Registration: Required.

Please register before the 15th of October by sending the following information:Name, title, affiliation and email address to: medhat.shehata[at]meduniwien.ac.at

Abstracts submission: We invite all experts in the field to submit their work for oral or poster presentation.Please send your abstract before the 15th of October to: medhat.shehata[at]meduniwien.ac.at

Abstract should be submitted in English as a word document and includes: Title, presenting author underlined, coauthors, affiliation, and abstract text (maximum 400 words for body of the abstract). Please state whether you intend to give an oral or poster presentation. A limited number of abstracts will be selected by the scientific committee for oral presentations and the presenting authors will be informed before the 22nd of October.

Posters (100x100 cm) should be hanged on the poster board before 9:00 am.Poster Prize: A junior scientist (Postdoc, PhD or diploma student) will be nominated by the scientific committee during the symposium for a poster prize. Please bring with you a PDF file of your poster for a potential oral presentation (10-15 min.) as a prize winner. We recommend that you send your PDF file in advance to medhat.shehata[at]meduniwien.ac.at

Publications: The abstracts will be published in the symposium proceedings. The authors of selected abstracts will be invited to submit their work for peer reviewed publication in Leukemia & Lymphoma and the International Journal of Cancer Microenvironment.

Looking forward to welcome you at the symposium

Medhat Shehata

On behalf of the organizing Committee

Ass. Prof. Dr. Medhat Shehata MD.

Head of Tumor Microenvironment Laboratory,

Executive Director of Drug & Target Screening Unit (DTSU), www.ccc.ac.at/dtsu

Comprehensive Cancer Center Vienna (www.ccc.ac.at)

Medical University of Vienna

Waehringer Guertel 18-20, Vienna, A-1090, Austria

Tel. Office: Tel.: +43 (0)1 40400 62170

Recent Publications from the CCC-DTSU:

PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.

Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L.

Nat Med. 2012 Oct 14. doi: 10.1038/nm.2966. [Epub ahead of print]

Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.

Gruber M, Fleiss K, Porpaczy E, Skrabs C, Hauswirth AW, Gaiger A, Vanura K, Heintel D, Shehata M, Einberger C, Thalhammer R, Fonatsch C, Jäger U.

Ann Hematol. 2011 Oct;90(10):1131-6. Epub 2011 May 27.

Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia.

Shehata M, Demirtas D, Schnabl S, Hilgarth M, Hubmann R, Fonatsch C, Schwarzinger I, Hopfinger G, Eigenberger K, Heintel D, Porpaczy E, Vanura K, Hauswirth A, Schwarzmeier JD, Gaiger A, Stilgenbauer S, Hallek M, Bilban M, Jäger U.

Leukemia. 2010 Dec;24(12):2122-7. Epub 2010 Oct 22. No abstract available.

Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.

Shehata M, Schnabl S, Demirtas D, Hilgarth M, Hubmann R, Ponath E, Badrnya S, Lehner C, Hoelbl A, Duechler M, Gaiger A, Zielinski C, Schwarzmeier JD, Jaeger U.

Blood. 2010 Oct 7;116(14):2513-21. Epub 2010 Jun 24.

[Tumor stem cell research - basis and challenge for diagnosis and therapy].

Karlic H, Herrmann H, Schulenburg A, Grunt TW, Laffer S, Mirkina I, Hubmann R, Shehata M, Marian B, Selzer E, Pfeilstöcker M, Pittermann E, Jäger U, Pehamberger H, Zielinski C, Valent P.

Wien Klin Wochenschr. 2010 Jul;122(13-14):423-36. Epub 2010 Jul 22. Review. German.

Neoplastic stem cells: current concepts and clinical perspectives.

Schulenburg A, Brämswig K, Herrmann H, Karlic H, Mirkina I, Hubmann R, Laffer S, Marian B, Shehata M, Krepler C, Pehamberger H, Grunt T, Jäger U, Zielinski CC, Valent P.

Crit Rev Oncol Hematol. 2010 Nov;76(2):79-98. Epub 2010 Feb 25. Review.

NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells.

Hubmann R, Düchler M, Schnabl S, Hilgarth M, Demirtas D, Mitteregger D, Hölbl A, Vanura K, Le T, Look T, Schwarzmeier JD, Valent P, Jäger U, Shehata M.

Br J Haematol. 2010 Mar;148(6):868-78. Epub 2009 Dec 8.

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.

Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jäger U, Gandhi V, Kay NE, Plunkett W, Burger JA.

Blood. 2009 Nov 12;114(20):4441-50. Epub 2009 Sep 17.

Liver X receptors interfere with cytokine-induced proliferation and cell survival in normal and leukemic lymphocytes.

Geyeregger R, Shehata M, Zeyda M, Kiefer FW, Stuhlmeier KM, Porpaczy E, Zlabinger GJ, Jäger U, Stulnig TM.

J Leukoc Biol. 2009 Nov;86(5):1039-48. Epub 2009 Aug 11.

Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes.

Vanura K, Le T, Esterbauer H, Späth F, Porpaczy E, Shehata M, Eigenberger K, Hauswirth A, Skrabs C, Krömer E, Schwarzinger I, Streubel B, Steininger C, Fonatsch C, Stilgenbauer S, Wagner O, Gaiger A, Jäger U.

Haematologica. 2008 Dec;93(12):1912-6. Epub 2008 Oct 6.

New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis.

Sagmeister S, Eisenbauer M, Pirker C, Mohr T, Holzmann K, Zwickl H, Bichler C, Kandioler D, Wrba F, Mikulits W, Gerner C, Shehata M, Majdic O, Streubel B, Berger W, Micksche M, Zatloukal K, Schulte-Hermann R, Grasl-Kraupp B.

Br J Cancer. 2008 Jul 8;99(1):151-9.

Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph+ acute leukaemia are not related to the leukaemic clone.

Wöhrer S, Rabitsch W, Shehata M, Kondo R, Esterbauer H, Streubel B, Sillaber C, Raderer M, Jaeger U, Zielinski C, Valent P.

Anticancer Res. 2007 Nov-Dec;27(6B):3837-41.

Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia.

Kainz B, Shehata M, Bilban M, Kienle D, Heintel D, Krömer-Holzinger E, Le T, Kröber A, Heller G, Schwarzinger I, Demirtas D, Chott A, Döhner H, Zöchbauer-Müller S, Fonatsch C, Zielinski C, Stilgenbauer S, Gaiger A, Wagner O, Jäger U.

Int J Cancer. 2007 Nov 1;121(9):1984-93.

Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process.

Letestu R, Rawstron A, Ghia P, Villamor N, Boeckx N, Boettcher S, Buhl AM, Duerig J, Ibbotson R, Kroeber A, Langerak A, Le Garff-Tavernier M, Mockridge I, Morilla A, Padmore R, Rassenti L, Ritgen M, Shehata M, Smolewski P, Staib P, Ticchioni M, Walker C, Ajchenbaum-Cymbalista F.

Cytometry B Clin Cytom. 2006 Jul 15;70(4):309-14. Erratum in: Cytometry B Clin Cytom. 2008 Jul;74(4):259. Leuven, Nancy Boeckx [corrected to Boeckx, Nancy].

Effect of combined spa-exercise therapy on circulating TGF-beta1 levels in patients with ankylosing spondylitis.

Shehata M, Schwarzmeier JD, Hilgarth M, Demirtas D, Richter D, Hubmann R, Boeck P, Leiner G, Falkenbach A.

Wien Klin Wochenschr. 2006 May;118(9-10):266-72.

Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression.

Bilban M, Heintel D, Scharl T, Woelfel T, Auer MM, Porpaczy E, Kainz B, Kröber A, Carey VJ, Shehata M, Zielinski C, Pickl W, Stilgenbauer S, Gaiger A, Wagner O, Jäger U; German CLL Study Group.

Leukemia. 2006 Jun;20(6):1080-8.

Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells.

Smolewski P, Duechler M, Linke A, Cebula B, Grzybowska-Izydorczyk O, Shehata M, Robak T.

Leuk Res. 2006 Dec;30(12):1521-9. Epub 2006 Apr 19.

Positive troponin T without cardiac involvement in inclusion body myositis.

Schwarzmeier JD, Hamwi A, Preisel M, Resl C, Preusser M, Sluga E, Horcher E, Shehata MM.

Hum Pathol. 2005 Aug;36(8):917-21.

High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia.

Heintel D, Kienle D, Shehata M, Kröber A, Kroemer E, Schwarzinger I, Mitteregger D, Le T, Gleiss A, Mannhalter C, Chott A, Schwarzmeier J, Fonatsch C, Gaiger A, Döhner H, Stilgenbauer S, Jäger U; CLL Study Group.

Leukemia. 2005 Jul;19(7):1216-23.

In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.

Duechler M, Linke A, Cebula B, Shehata M, Schwarzmeier JD, Robak T, Smolewski P.

Eur J Haematol. 2005 May;74(5):407-17.

Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera.

Kees M, Wiesbauer F, Gisslinger B, Wagner R, Shehata M, Gisslinger H.

Thromb Haemost. 2005 Jan;93(1):70-5.

Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia.

Schwarzmeier JD, Hubmann R, Düchler M, Jäger U, Shehata M.

Leuk Lymphoma. 2005 Feb;46(2):157-65. Review.

Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2.

Duechler M, Shehata M, Schwarzmeier JD, Hoelbl A, Hilgarth M, Hubmann R.